{"metadata": {"source": "pubchem", "title": "Cannabidiol | C21H30O2 | CID 644019 - PubChem", "description": "Cannabidiol | C21H30O2 | CID 644019 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/644019", "drug": "CBD", "cid": 644019, "char_count": 55, "word_count": 8, "doc_id": "doc_22", "num_chunks": 1, "chunk_id": "22::chunk_0", "document_index": 22, "latency_s": 0.0017211999947903678, "prompt_toks": 212, "completion_toks": 84, "relevance_score": 0.0058199596}, "content": "Drug: CBD | cid: 644019\nSource: pubchem | Source description: Cannabidiol | C21H30O2 | CID 644019 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PUGVIEW.ServerBusy Too many requests or server too busy\n\n\n                    Context: \n                    This chunk indicating \"PUGVIEW.ServerBusy Too many requests or server too busy\" appears within the webpage as an error message possibly displayed during server overload or request limits are exceeded. It highlights a temporary issue affecting access to the comprehensive chemical data and resources, which are central to the webpage's purpose of providing detailed scientific information on compounds. Recognizing this message helps in understanding potential disruptions in retrieving or viewing the full content.\n                "}
{"metadata": {"source": "psychonaut_CSV", "row": 22, "doc_id": "doc_251", "num_chunks": 4, "chunk_id": "251::chunk_0", "document_index": 251, "latency_s": 1.0339968999905977, "prompt_toks": 1047, "completion_toks": 57, "relevance_score": 0.0049245106}, "content": "Drug: Unknown | cid: N/A\nSource: psychonaut_CSV | Source description: ?\n\n                    Text: \n                    drug: CBD\npsychonaut_name: CBD\npsychonaut_url: https://psychonautwiki.org/wiki/CBD\nInfobox: Cannabidiol | Chemical Nomenclature | Common names | Cannabidiol, CBD, Epidiolex | Substitutive name | Cannabidiol | Systematic name | (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol | Class Membership | Psychoactive class | Cannabinoid | Chemical class | Cannabinoid | Routes of Administration | WARNING: | Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. | See responsible use section | . | ⇣ | Oral | Dosage | Threshold | 2 mg | Light | 5 - 15 mg | Common | 15 - 30 mg | Strong | 30 - 60 mg | Heavy | 60 mg + | Duration | Total | 1.5 - 4 hours | Come up | 15 - 30 minutes | Offset | 1 - 1.5 hours | DISCLAIMER | : | PW's | dosage | information is gathered from users and | resources | for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy. | Interactions\n\n\n                    Context: \n                    This chunk provides detailed chemical, dosing, and administration information for CBD, including its common names, chemical nomenclature, safety warnings, dosage thresholds, and pharmacological routes, serving as a core reference section within the full resource on CBD's effects, chemistry, and harm potential.\n                "}
{"metadata": {"source": "psychonaut", "title": "MDMA - PsychonautWiki", "description": "3,4-Methylenedioxymethamphetamine (also known as ecstasy, E, XTC, emma, molly, mandy, pingers, and MDMA) is a classical entactogen substance of the amphetamine class. \nIt is the most well-known and widely-used member of the entactogens, a diverse group that includes MDA, methylone, 4-MMC, and 6-APB. It produces its effects by promoting the release of serotonin, dopamine, and norepinephrine in the brain, particularly serotonin.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/MDMA", "drug": "MDMA", "cid": 1615, "char_count": 74065, "word_count": 10533, "doc_id": "doc_82", "num_chunks": 98, "chunk_id": "82::chunk_66", "document_index": 82, "latency_s": 0.9158033999992767, "prompt_toks": 18890, "completion_toks": 86, "relevance_score": 0.00053578056}, "content": "Drug: MDMA | cid: 1615\nSource: psychonaut | Source description: 3,4-Methylenedioxymethamphetamine (also known as ecstasy, E, XTC, emma, molly, mandy, pingers, and MDMA) is a classical entactogen substance of the amphetamine class. \nIt is the most well-known and widely-used member of the entactogens, a diverse group that includes MDA, methylone, 4-MMC, and 6-APB. It produces its effects by promoting the release of serotonin, dopamine, and norepinephrine in the brain, particularly serotonin.\n\n                    Text: \n                    Legal status\n\nInternationally, MDMA was added to the UN Convention on Psychotropic Substances as a Schedule I controlled substance in February 1986.[86]\n\nAustralia: MDMA is a Schedule 8 (Controlled Drugs) drug in Australia, starting July 1st 2023. [87] Personal quantities under 1.5 grams (or 5 single doses, such as when in tablet form) are decriminalized in the Australian Capital Territory (ACT) as of 28 October 2023.[88]\n\nAustria: MDMA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).[89]\n\nBelgium: MDMA is illegal to possess, produce and sell in Belgium.[90]\n\nBrazil: MDMA is illegal to possess, produce and sell under Portaria SVS/MS nº 344.[91]\n\nCanada: MDMA is a Schedule I drug in Canada.[92]\n\nDenmark: MDMA is illegal to possess, produce and sell in Denmark.[93]\n\nEgypt: MDMA is a Schedule III drug in Egypt.[citation needed]\n\nFinland: MDMA is illegal to possess, produce and sell in Finland.[citation needed]\n\n\n                    Context: \n                    This section details the legal status of MDMA in various countries worldwide, providing specific classifications and recent regulatory changes. It is a key part of the overall document, which covers MDMA's effects, risks, and history, offering crucial information for harm reduction and legal considerations for users or researchers. Notably, it includes international, national, and regional legal classifications, including recent updates such as Australia's new scheduling as of July 2023.\n                "}
